332 related articles for article (PubMed ID: 33769675)
1. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
[TBL] [Abstract][Full Text] [Related]
3. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
[TBL] [Abstract][Full Text] [Related]
5. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Ji L; Liu Y; Miao H; Xie Y; Yang M; Wang W; Mu Y; Yan P; Pan S; Lauring B; Liu S; Huyck S; Qiu Y; Terra SG
Diabetes Obes Metab; 2019 Jun; 21(6):1474-1482. PubMed ID: 30830724
[TBL] [Abstract][Full Text] [Related]
7. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
Budoff MJ; Davis TME; Palmer AG; Frederich R; Lawrence DE; Liu J; Gantz I; Derosa G
Diabetes Ther; 2021 May; 12(5):1279-1297. PubMed ID: 33721213
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Gallo S; Charbonnel B; Goldman A; Shi H; Huyck S; Darekar A; Lauring B; Terra SG
Diabetes Obes Metab; 2019 Apr; 21(4):1027-1036. PubMed ID: 30614616
[TBL] [Abstract][Full Text] [Related]
10. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
[TBL] [Abstract][Full Text] [Related]
11. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Cannon CP; McGuire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG;
Am Heart J; 2018 Dec; 206():11-23. PubMed ID: 30290289
[TBL] [Abstract][Full Text] [Related]
12. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
[TBL] [Abstract][Full Text] [Related]
13. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Dagogo-Jack S; Frederich R; Liu J; Cannon CP; Shi H; Cherney DZI; Cosentino F; Masiukiewicz U; Gantz I; Pratley RE
J Clin Endocrinol Metab; 2023 Jul; 108(8):2042-2051. PubMed ID: 36702781
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Pratley R; Dagogo-Jack S; Charbonnel B; Patel S; Hickman A; Liu J; Tarasenko L; Pong A; Ellison MC; Huyck S; Gantz I; Terra SG
Diabetes Obes Metab; 2020 Dec; 22(12):2276-2286. PubMed ID: 32700421
[TBL] [Abstract][Full Text] [Related]
15. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Liu J; Patel S; Cater NB; Wu L; Huyck S; Terra SG; Hickman A; Darekar A; Pong A; Gantz I
Diabetes Obes Metab; 2020 Apr; 22(4):574-582. PubMed ID: 31797522
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
Diabetes Obes Metab; 2022 Jul; 24(7):1245-1254. PubMed ID: 35266296
[TBL] [Abstract][Full Text] [Related]
18. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
Diabetes Obes Metab; 2022 Jun; 24(6):1114-1122. PubMed ID: 35233908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Wu L; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
Curr Med Res Opin; 2020 Aug; 36(8):1277-1284. PubMed ID: 32324082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
